Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-Seq and ChIP-Seq studies in PLC-PRF cells

ABSTRACT: ATAC-Seq and ChIP-Seq studies in PLC-PRF cells

PROVIDER: PRJNA595404 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10683105_1.fastq.gz	Fastqsanger.gz
	SRR10683105_2.fastq.gz	Fastqsanger.gz
	SRR10683106_1.fastq.gz	Fastqsanger.gz
	SRR10683106_2.fastq.gz	Fastqsanger.gz
	SRR10683107_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

ATAC-seq profiling of open chromatin in PLC-PRF cells

Project description:ATAC-seq profiling of open chromatin in PLC-PRF cells

| PRJNA595430 | ENA

PLC/PRF/5 cells ChIP on CHIP

Project description:PLC/PRF/5 cells were harvested for chromatin immunoprecipitation followed by CHIP analysis performed on Aligent platform.

2017-07-10 | GSE100968 | GEO

RRBS of PCK1 knockout in PLC/PRF/5

Project description:RRBS analysis of Parental and PCK1 knockout groups of PLC/PRF/5 cells.

2023-07-06 | GSE221725 | GEO

Expression data from hepatitis E virus inoculated PLC/PRF/5 cells

Project description:Hepatitis E virus (HEV) is an important causative pathogen of acute hepatitis. Because of the absence of an in vitro culture system for HEV, research has been greatly impeded. And interaction between HEV and host cells was mainly studied by tansfection/transinfection system, such as Adeno virus transinfection system. We developed an in vitro culture system for HEV in PLC/PRF/5 cells. With this in vitro culture system, we studied the gene expression profile change by HEV infection. Using a microarray assay, we analysed genes of PLC/PRF/5 cells, whose transcription level could be changed by HEV infection. Five flasks of PLC/PRF/5 cells inoculated with HEV were used as test sample, and five flasks inoculated with serum-free DMEM/199 medium were used as control samples. Both test and control flasks were cultured under the same conditions. Sixty days after inoculation, the test and control flasks was resolved with Trizol and analysed with Affymetrix HG-U133 Plus 2 array.

2014-01-01 | E-GEOD-53731 | biostudies-arrayexpress

RNAi knock down of Hepatitis B viral gene expression in human HepG2.2.15 or PLC/PRF/5 cells

Project description:Gene expression profiling comparisons of HepG2.2.15 or PLC/PRF/5 cells either mock (M) transfected or transfected with 0.2 microM S2 RNA or Scrambled (SCR) siRNA were carried out in duplicate 48 hours after transfection. The experiments were carried out in duplicate (a and b). The following combinations of RNA were used on 2 slides each: 1. 2.2.15 cells: mock transfection (reference) versus S2 treatment (test) 2. 2.2.15 cells: mock transfection (reference) versus Scr treatment (test) 3. 2.2.15 cells: Scr treatment (reference) versus S2 treatment (test) 4. PLC/PRF/5 cells: mock transfection (reference) versus S2 treatment (test) 5. PLC/PRF/5 cells: mock transfection (reference) versus Scr treatment (test) 6. PLC/PRF/5 cells: Scr treatment (reference) versus S2 treatment (test)

2005-11-03 | E-SMDB-2880 | biostudies-arrayexpress

The RNA-seq of HCC specimens and the RIP-seq of HNRNPD in PLC cells and WT (DMSO or Compound C) and circLARP1B-Def (DMSO) PLC/PRF/5 cells

Project description:To investigate functional transcripts in metastatic HCC, we performed high-throughput RNA sequencing (RNA-seq) of tumors from 3 metastatic HCC and 3 non-metastatic HCC. And we performed RIP-seq human PLC/PRF/5 cells to investigate the HNRNPD binding transcripts. To investigate function of circLARP1B on AMPK pathway, we performed high-throughput RNA sequencing (RNA-seq) of WT (DMSO or Compound C) and circLARP1B-Def (DMSO) PLC/PRF/5 cells.

2023-04-02 | GSE217403 | GEO

CDC7 inhibition in PLC/PRF/5 cells

Project description:Purpose: to analyze gene expression in XL413 treated liver cancer cells. Methods: PLC/PRF/5 cells are treated with XL413 (10uM) for 96 hours .For RNA sequencing, the library was prepared using TruSeq RNA sample prep kit according to the manufacturer’s protocol (Illumina). Gene set enrichment analysis was performed using gene set enrichment analysis software.

2021-09-12 | GSE183751 | GEO

MeRIP-seq analysis for CSTF2 knockout in HUH7 and PLC/PRF/5 cell lines

Project description:CSTF2 has been shown to have a certain oncogenic effect in hepatocellular carcinoma, but its mechanism remains unclear. Previous studies have suggested that CSTF2 can shorten the 3' untranslated region (3'UTR) of target genes. Considering that the 3'UTR contains numerous m6A modification sites, we hypothesize that CSTF2 may regulate mRNA m6A modification. We performed MeRIP-seq analysis to investigate the changes in m6A modification in CSTF2 knockout HUH7 and PLC/PRF/5 cell lines.

2024-05-30 | GSE268346 | GEO

Expression data from hepatitis E virus inoculated PLC/PRF/5 cells

2014-01-01 | GSE53731 | GEO

Transcriptome Analysis of PLC/PRF/5 cells Infected with Adenovirus Overexpression SCL27A5

Project description:Purpose:To understand the change in cellular metabolism and function for the overxepression of SCL27A5 in hepatoma cells. Methods:Total RNAs of AdSLC27A5- or AdGFP-infected PLC/PRF/5 cells were extracted using TRIzol (Invitrogen), following the manufacturer’s instructions. RNA-seq and bioinformatic data analysis were performed by Shanghai Novel Bio Ltd. Briefly, strand-specific RNA-seq libraries were prepared using the Total RNA-seq (H/M/R) Library Prep Kit (Vazyme Biotech, Nanjing, China) and were sequenced on a HiSeq X Ten sequencing platform. Raw reads in FASTQ format were subjected to quality control using FastQC. RNA-seq reads were aligned to the reference genome using Bowtie. Uniquely mapped reads were used for further analysis. Gene expression levels are expressed as RPKM (reads per kilobase per million reads) and differences in gene expression were calculated with rSeq. Results:There were 17 genes differentially expressed in AdSLC27A5-infected PLC/PRF/5 cells compare to the GFP control group (fold change >1.5 or < 0.667; FDR < 0.05).

2023-07-01 | GSE117823 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data